CORRECTION: Correct Ticker for Talaris Therapeutics Is 'TALS'
$TAL
$TALS
Other Consumer Services
Real Estate
Biotechnology: Pharmaceutical Preparations
Health Care
CORRECTION: Correct Ticker for Talaris Therapeutics Is 'TALS'
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/30/2026 | $18.00 | Neutral → Outperform | Macquarie | |
| 10/30/2025 | $16.00 | Neutral → Overweight | Analyst | |
| 6/27/2025 | $11.54 | Buy → Neutral | Citigroup | |
| 4/25/2025 | $10.90 | Outperform → Neutral | Macquarie | |
| 4/24/2025 | $16.00 → $11.00 | Overweight → Neutral | Analyst | |
| 5/29/2024 | $16.00 | Buy | HSBC Securities | |
| 1/26/2024 | Outperform → Buy | CLSA | ||
| 1/25/2024 | $10.00 → $15.00 | Neutral → Overweight | JP Morgan |
Macquarie upgraded TAL Education from Neutral to Outperform and set a new price target of $18.00
Analyst upgraded TAL Education from Neutral to Overweight and set a new price target of $16.00
Citigroup downgraded TAL Education from Buy to Neutral and set a new price target of $11.54
BEIJING, Jan. 29, 2026 /PRNewswire/ -- TAL Education Group (NYSE:TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the third quarter of fiscal year 2026 ended November 30, 2025. Highlights for the Third Quarter of Fiscal Year 2026 - Net revenues were US$770.2 million, compared to net revenues of US$606.4 million in the same period of the prior year. - Income from operations was US$93.1 million, compared to loss from operations of US$17.4 million in the same period of the prior year. - Non-GAAP income from operations, which excluded share-based compensation expenses, was US$104.0 million, compared to non-GAAP loss
BEIJING, Jan. 12, 2026 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE:TAL), a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the third quarter of fiscal year 2026 ended November 30, 2025, before the market opens on Thursday, January 29, 2026. The Company will host a corresponding conference call and live webcast at 7:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing Time) on Thursday, January 29, 2026. Please note that you will need to pre-register for conference call participation at https://dpregister.com/sreg/10205339/102f9a80ea5. Upon registration, you will receive an email containing participant dial
BEIJING, Oct. 30, 2025 /PRNewswire/ -- TAL Education Group (NYSE:TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the second quarter of fiscal year 2026 ended August 31, 2025 and issued notice of Annual General Meeting. Highlights for the Second Quarter of Fiscal Year 2026 Net revenues were US$861.4 million, compared to net revenues of US$619.4 million in the same period of the prior year.Income from operations was US$96.1 million, compared to income from operations of US$47.6 million in the same period of the prior year.Non-GAAP income from operations, which excluded share-based compensation expenses, was US$10
144 - TAL Education Group (0001499620) (Subject)
6-K - TAL Education Group (0001499620) (Filer)
6-K - TAL Education Group (0001499620) (Filer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
3 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
BEIJING, Jan. 29, 2026 /PRNewswire/ -- TAL Education Group (NYSE:TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the third quarter of fiscal year 2026 ended November 30, 2025. Highlights for the Third Quarter of Fiscal Year 2026 - Net revenues were US$770.2 million, compared to net revenues of US$606.4 million in the same period of the prior year. - Income from operations was US$93.1 million, compared to loss from operations of US$17.4 million in the same period of the prior year. - Non-GAAP income from operations, which excluded share-based compensation expenses, was US$104.0 million, compared to non-GAAP loss
BEIJING, Jan. 12, 2026 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE:TAL), a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the third quarter of fiscal year 2026 ended November 30, 2025, before the market opens on Thursday, January 29, 2026. The Company will host a corresponding conference call and live webcast at 7:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing Time) on Thursday, January 29, 2026. Please note that you will need to pre-register for conference call participation at https://dpregister.com/sreg/10205339/102f9a80ea5. Upon registration, you will receive an email containing participant dial
BEIJING, Oct. 30, 2025 /PRNewswire/ -- TAL Education Group (NYSE:TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the second quarter of fiscal year 2026 ended August 31, 2025 and issued notice of Annual General Meeting. Highlights for the Second Quarter of Fiscal Year 2026 Net revenues were US$861.4 million, compared to net revenues of US$619.4 million in the same period of the prior year.Income from operations was US$96.1 million, compared to income from operations of US$47.6 million in the same period of the prior year.Non-GAAP income from operations, which excluded share-based compensation expenses, was US$10
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors. "Karen's long track record of developing and commercializing novel therapies and her wide-ranging industry experience make her a valuable addition to our Board of Directors," said Francois Nader, M.D., Chairman of the Board of Talaris. "I am pleased to welcome her to the team an
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)